[ad_1]
Hamid bin Harmal al-Shamsi, an oncology consultant at Tawam hospital, confirmed that the new drug against Vitracopy, recently approved by the US Food and Drug Administration, was ineffective, denying the news that Rajat was finally talking of its capacity. On cancer treatment at its source, it addresses the genes of cancerous tumors, regardless of their origin in the human body.
Al Shamsi was surprised by the video that he recorded for himself, the social networking sites and the application of Watts Ab, cancer patients, highlighting the existence of many points and facts to be clarified regarding this medication, including that it is not effective for cancer patients from the first, second and third, for cancer patients who have a spread of the disease in the body, or which we call "Phase IV" only.
"All fourth-stage cancer patients will not respond to this drug, only about 1% of patients will respond," he said. "The answer will not be complete or complete, because it only happened in one or two cases, the permanent response that we see in chemicals and other drugs." is neither a panacea nor the final solution for cancer patients. "
Al Shamsi explained that "the identification of the 1% of patients who can benefit from this drug is to perform specific tests to ensure that the patient has specific genetic mutations. These mutations have been commonplace and available in the UAE for several years. "
"Viagracafe is not the first gene therapy," he said. "There used to be other genetically modified drugs, but what happened with the new drug was a kind of amplification," he said. "This is a fantastic step for some patients with stage IV cancer and carriers of a specific genetic mutation called NTRK, but the goal of the demonstration is to show that not all patients can benefit from this treatment. "
Al-Shamsi urged patients, when seeking information, to contact their physician, the media, social networking sites and reports before publishing any information that could lead to adverse reactions. particularly in cancer patients. The US Food and Drug Administration announced at the end of November that it was marketing the world's first drug to treat cancer, from its source in adults and children. Vitracave depends on treatment genetic mutations of cancerous tumors, regardless of the type or location of the disease.
"Approval of the authorization and the introduction of drugs are an important step in the treatment of cancer, as they treat it from its source and treat the gene base of cancerous tumors, regardless of their origin in the human body "said Scott Gottlieb, VITRAKFI® helps treat people with different cancers, but they present common hereditary mutations.
Hamid Bin Harmal Al Shamsi is the Chief Medical Adviser of the Head of State for Physicians of Excellence, Consultant in Internal Medicine, Oncology and Cancer, Associate Professor in the Faculty of Medicine of the University from Sharjah, where he spent 20 years studying medicine and specialized medical and scientific research training. Cancer and oncology.
Al Shamsi is the first national physician (citizen or resident) to receive five specialized board of directors certificates in the fields of internal medicine, cancer and tumors from the United States, Canada and the United Kingdom. He also holds a postdoctoral certificate from the University of McMaster, Canada, specializing in tumors, gastrointestinal cancer and metastatic cancer.
Success rate
Dr. Yousef Al-Zayyab, executive director of Tawam Hospital, told Emirates Al-Youm that the new Vitrakafi drug was only used in the hospital as part of experimental experiments and that 39, he had not yet been paid to cancer patients to monitor the effects. Less than 1%.
• Al-Shamsi requested clarification before publishing any information that could lead to adverse effects.
Source link
